U.S. Communications Stock News

Key Insights Given the large stake in the stock by institutions, SkyWater Technology's stock price might be vulnerable...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...

Rambus Inc. ( NASDAQ:RMBS ) shareholders have seen the share price descend 12% over the month. But that doesn't...

NVR (NVR) posted net profit margins of 14.2%, down from 16.2% last year, highlighting pressure on profitability even as annual earnings have grown 10.8% over the past five years. The most recent year saw negative earnings growth, and with a Price-To-Earnings ratio of 14.5x, which is well above industry and peer averages, the market is pricing the stock at $7,697.16, above the estimated fair value of $6,678.01. Despite earnings being described as high quality, investors may be weighing...

Lockheed Martin (LMT) posted a net profit margin of 5.7%, down from 9.4% last year, with average annual earnings slipping 4.6% over the past five years. While the recent trend shows slower growth, forecasts call for annual profit growth of 14.3% and revenue growth of 3.2% per year, both lagging the broader US market. Despite this, the company’s earnings quality remains high, and the stock stands out for its attractive valuation, solid dividend, and continued growth expectations, helping to...

Thinking about what to do with Reliance stock right now? You’re not alone. With so much buzz in the market and news cycles pushing headlines faster than ever, it’s easy to feel both curious and cautious. Reliance has been a favorite among long-term investors, and for good reason. The last five years alone saw the stock rally a remarkable 180.3%. Even over the past three years, despite a few bumps, Reliance delivered a strong 48.1% gain. However, more recently, things have been a bit choppier...

Danaher (DHR) saw its earnings decline by 5.6% per year over the past five years, and most recently reported negative earnings growth again. Net profit margins narrowed to 14.4%, down from 16.6% last year, while shares currently trade at $218.10, below the estimated fair value of $233.28. Revenue is expected to grow at 5.2% per year, which trails the US market average of 10%. However, earnings are forecast to accelerate at 16.7% annually, outpacing the 15.5% average for the broader market...

So, you’re eyeing Kaspi.kz and wondering whether the current stock price is an opportunity or just a value trap. It’s not an easy call, especially when the numbers are playing tricks. Over the past year, the share price has slumped by 31.1%, and year-to-date it’s down 25.1%. Even the last 30 days saw a further drop of 13.5%. Those red numbers can shake anyone’s confidence. But here’s what makes this interesting: go back three years, and Kaspi.kz has delivered a total return of 49.8%. This...

Wondering what your next move should be with TowneBank stock? You are not alone. With the share price at $33.62 as of the last close, curiosity is high among investors trying to figure out if there is still upside after some intriguing market activity. If you zoom out, TowneBank has given its long-term holders some bragging rights, delivering a solid 122.8% return over the past five years. Even its three-year performance stands strong at 23.1%. However, not all periods have been as positive,...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Frequency Electronics, Inc. ( NASDAQ:FEIM ) shareholders might be concerned after seeing the share price drop 11% in...

Old National Bancorp (ONB) posted an average annual earnings growth of 21.2% over the past five years, with its latest yearly increase at 9.1%. Net profit margins held at 29.1%, just off last year’s 29.2%. Looking ahead, forecasts call for ONB’s earnings to rise 22.5% per year and revenue to climb 9.5% annually, both stacking up well against broader U.S. market expectations. See our full analysis for Old National Bancorp. Now it’s time to see how these headline numbers compare with the...

Armata Pharmaceuticals (ARMP) just reported encouraging Phase 2a trial results for its experimental IV bacteriophage therapy, AP-SA02, targeting complicated Staphylococcus aureus bacteremia. The data was revealed during a presentation at IDWeek 2025. See our latest analysis for Armata Pharmaceuticals. News of Armata’s clinical breakthrough sent its share price surging 103% in a single day, fueling a remarkable 261% gain for investors year-to-date. Recent momentum has reversed previous years...

Amidst a backdrop of U.S.-China trade tensions and ongoing government shutdown, major stock indexes have ended lower as investors digest recent earnings reports. In this challenging market environment, identifying promising small-cap stocks can be pivotal, especially those that show resilience and potential for growth despite broader economic pressures.

As the U.S. market grapples with a mix of earnings reports and renewed U.S.-China trade tensions, major indices like the Nasdaq, Dow Jones Industrial Average, and S&P 500 have recently faced downward pressure. In such a volatile environment, identifying high growth tech stocks requires careful consideration of their resilience to geopolitical issues and their ability to innovate amidst economic challenges.

Major stock indexes in the United States recently ended lower as investors grappled with earnings reports and renewed U.S.-China trade tensions. Despite these challenges, penny stocks remain an intriguing investment option for those seeking growth opportunities in smaller or newer companies. While the term "penny stocks" might seem outdated, these investments can still offer surprising value when backed by strong financials, providing a potential mix of stability and long-term potential.

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

If you have Varonis Systems on your watchlist, you are not alone. Plenty of investors are debating their next move after what has been an eventful run for the stock. Over the past year, shares are up 8.2%, and if you zoom out to a three-year lens, the jump is a staggering 128.8%. That kind of long-term gain stands out, especially considering this year alone has already seen a robust 38.1% rise. Even in the shorter term, Varonis has eked out steady growth, nudging up 1.1% over the last week...

If you have been eyeing Safehold lately, you are hardly alone. Whether you already own shares or are considering your options, the recent price swings have probably caught your attention. Safehold closed at $15.84 and has experienced a bumpy ride, with a modest 1.7% uptick this past week, but still lagging over the longer term. The stock has dropped 1.5% in the last month, is down 15.2% since the start of the year, and has lost a notable 29.3% across the past twelve months. Looking back even...

Elevance Health (ELV) delivered revenue growth forecasts of 3.2% annually, trailing the US market’s expected pace of 10% per year. EPS is projected to rise 10.8% each year, again underperforming the 15.5% growth outlook for the broader market. The company’s net profit margin compressed to 2.8%, down from 3.7% a year ago, and recent negative earnings growth makes year-over-year acceleration less meaningful compared to longer-term trends. Shares are trading at $345.21, well below an estimated...

If you’re standing at the crossroads wondering whether to buy, sell, or simply wait when it comes to Beacon Financial stock, you’re not alone. The past few months have been anything but predictable. With the share price closing at $24.22 and marking a dip of 2.8% over the last week, some investors might see warning signs, but others see a window of opportunity. Step back just a little, and a 3.2% slide over the past month paints a similar picture, with the year-to-date return off by 13.3%...

The Morning Bull - US Market Morning Update Thursday, Oct, 23 2025 US equity futures are mixed this morning as investors navigate low Treasury yields and shifting interest rate expectations. With the 10-year yield parked near one-year lows and a widely anticipated Federal Reserve rate cut on the horizon, the focus turns to what easier policy might mean for consumer activity and borrowing. The upcoming inflation report is set to influence sentiment, prompting investors to weigh whether lower...

Perspective Therapeutics recently presented updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET for advanced neuroendocrine tumors at the ESMO Congress 2025, highlighting a 44% objective response rate in Cohort 2 and a favorable safety profile with no dose limiting toxicities. An important insight is that the therapy maintained disease control for most patients at 41 weeks median follow-up, but investor reactions signaled higher expectations for efficacy...

Key Insights Significant insider control over TuHURA Biosciences implies vested interests in company growth A total of...